Ignite Creation Date:
2025-12-25 @ 3:20 AM
Ignite Modification Date:
2025-12-26 @ 1:58 AM
Study NCT ID:
NCT00704405
Status:
COMPLETED
Last Update Posted:
2018-10-09
First Post:
2008-06-23
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-03-27
Start Date Type:
ACTUAL
Primary Completion Date:
2012-03-26
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-09-10
Completion Date Type:
ACTUAL
First Submit Date:
2008-06-23
First Submit QC Date:
None
Study First Post Date:
2008-06-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-09-26
Results First Submit QC Date:
None
Results First Post Date:
2014-09-29
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-09-10
Last Update Post Date:
2018-10-09
Last Update Post Date Type:
ACTUAL